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Objective: To describe the characteristics, across all ages, of powered wheelchair users and 
the assistive technology prescribed by a regional specialist wheelchair service  
Design: Cross-sectional study 
Setting: Regional wheelchair service provided to those fulfilling strict eligibility criteria by a 
National Health Service serving a population of 3 million. 
Participants: 544 Electric Powered Indoor/outdoor wheelchair (EPIOC) users. 
Interventions: Not applicable 
Main Outcome Measures: Demographic, clinical/diagnostic details of EPIOC recipients 
including pain, (kypho)scoliosis and ventilators. Technical features including specialised 
(adaptive) seating (SS), tilt in space (TIS), and modified control systems. Factors were related 
to age groups: 1 (0-15), 2 (16-24), 3 (25-54), 4 (55-74) and 5 (75+).  
Results: 262 men mean age 41.7 (range 8-82, sd 20.7) and 282 women mean age 47.2 (range 
7-92, sd 19.7) years were studied. Neurological/neuromuscular conditions predominated 
(81%) with cerebral palsy (CP) (18.9%) and multiple sclerosis (16.4%). Conditions 
presenting at birth or during childhood constituted 39%. 99 had problematic pain, 83 a 
(kypho)scoliosis and 11 used ventilators.  
SS was provided to 169 users (31%), the majority had CP or muscular dystrophy. TIS was 
used by 258 (53%). Younger people were more likely to receive TIS than older ones. Only 92 
had SS and TIS, mean age 29 (range 8-72, sd 17.8) years.  52 used modified control systems.  




Discussion: The diversity of EPIOC users across age and diagnostic groups is shown. Their 
complex interrelationships with these technical features of EPIOC prescription are explored. 
Younger users were more complex due to age-related changes. 
Conclusions: This study provides outcomes of the EPIOC prescription for this heterogeneous 
group of very severely disabled people.   




AT  Assistive technology 
CP  Cerebral Palsy 
CVD  Cerebrovascular Disease 
EPIOC(s)  Electric powered indoor/outdoor wheelchair(s) 
MD  Muscular Dystrophy 
MS  Multiple Sclerosis 
NNC   Neurological or neuromuscular conditions  
NHS  National Health Service 
PM  Powered mobility 
RA  Rheumatoid Arthritis 
SB  Spina Bifida 
SCI  Spinal Cord Injury  
SS  Specialised seating  
TIS  Tilt-in-space  
UK  United Kingdom 





The benefits of powered mobility (PM) for people with severe disabilities are now better 
understood. By using powered wheelchairs, individuals can experience greater participation 
in activities such as education1-4 or work1-3,5, and a range of social activities such as 
shopping1-3;6;7;7;8, church going1;2;6;9, socialising with family and friends1;2;6;9;10 and accessing 
healthcare facilities2;6;9;11. In addition, the increased mobility provided by PM enhances 
quality of life and wellbeing5;10;12. Benefits to carers have also been reported2;5;9;11. However, 
it has been noted that there are problems associated with powered mobility (PM). For some 
wheelchair users (referred to as users), pain and discomfort remain problematic1;13;14  as do 
difficulties with transport5;9 and equipment breakdown or accidents1;2;15. Nonetheless, 
successful community dwelling and interaction involves activities that are dependent on a 
successful PM prescription minimising immobility. Studies generally have involved small 
numbers of users and are usually exploratory in nature, an  issue also identified in the review 
of Greer et al16.  
Recently, gaps have been identified and recommendations made for future studies to 
strengthen the evidence base. Research suggestions are to include people with different 
physical limitations, needs and goals16. Lack of standardisation of service delivery in the 
published literature is perceived as a problem to improving practice and understanding who 
might benefit from PM. Such information is needed to develop standards and guidelines16, 
and to identify groups of users who would justify additional expense, an issue of concern for 
policy makers and  payers16. 
There is a need to capture data from greater numbers representative of the population of 
wheelchair users17. Whilst such populations have been described18, the diagnoses, age and 
gender of a large and specific population of powered wheelchair users is lacking. Objectively 
verified data are needed for these factors as declarative data gathered through self-report 




surveys have been criticized for biases18. Descriptive studies are needed to identify the issues 
important to effective matching of severely disabled users who have complex needs with 
appropriate PM.  
In 1996 the United Kingdom (UK) government directed the National Health Service (NHS) 
to provide electric powered indoor/outdoor wheelchairs (EPIOCs) to people with severe and 
complex disabilities who fulfilled strict criteria, fully funded by the government2. In essence 
those unable to walk around their home unaided, unable to self propel and able to utilise the 
chair independently are eligible.  They are similar to those required by Medicare 19 .The 
EPIOC provided is based on functional need and the potential benefit. Scooters are not 
provided by the NHS. Users may choose to take the value of the prescribed EPIOC in 
vouchers and purchase a chair privately20. 
A Specialist Wheelchair Service was set up in 1997 to provide EPIOCs for a geographical 
region spreading from inner London, the north west suburbs and rural Home Counties. This 
area comprised 11 health primary care trusts serving a population of approximately three 
million.  
This cross-sectional study aims to describe the clinical characteristics and assistive 
technology (AT) prescribed across the age span of users of a fleet of EPIOCs at a given time, 
as suggested by Karmakar et al7. We studied a large group of community-dwelling EPIOC 
users who by definition are the most severely mobility disabled people. This contrasts with 
studies that include those able to use scooters6;17 or are able to walk indoors6. Furthermore, 
these studies did not include any clinical assessment by health professionals. The study by 
Karmarkar et al7, although including assessment by a sophisticated multiprofessional 
rehabilitation team, was limited to older users. 
Methods 




Potential users were referred from locally based NHS wheelchair services. Clinic records 
including assessment and wheelchair equipment of those provided with an EPIOC, and still 
using it, were reviewed in June 2007 and data were extracted. Average time from the initial 
assessment in clinic to the case note review was 72.4 (range 0-1166, sd 73.2) months.  
The data relevant to this study had been recorded by health professionals following a physical 
examination and assessment and consisted of:- 
Demographic data  
• age at initial assessment 
• gender  
Medical factors 
• Major diagnosis contributing to the need for a wheelchair as described previously2 but 
with the addition of a category for inherited metabolic conditions. 
• Ventilator issues  
• Problematic pain – that needed intervention(s). 
• (Kypho)scoliosis 
Users with multiple sclerosis (MS), cerebral palsy (CP), muscular dystrophy (MD), 
cerebrovascular disease (CVD), other neurological conditions, spina bifida (SB), spinal cord 
injury (SCI) and polio were grouped together as having neurological or neuromuscular 
conditions (NNCs). 
Wheelchair factors 




• Specialised seating (SS) – that which is needed by people who require a wheelchair 
but due to instability or deformity need additional support in order to function21, 
(similar to that of adaptive seating22)  
• Tilt-in-space (TIS) 
• Complex controls e.g. central joystick / tray mounted controls, head controls, switch 
controls, non-standard control system,  interfacing with other assistive technology 
Methods of analysis 
Users were grouped by age according to the categories published by Warren23.  We added 
one further category, ‘under 16 years of age’ (school children). These will be referred to as: 
Group 1 (0-15 schoolchildren); Group 2 (16-24 school leavers and young people); Group 3 
(25-54 those developing families, jobs and careers); Group 4 (55-74 those reaching the end of 
employment and in active retirement); Group 5 (75 and older).  
Age group data were analysed to describe proportions and frequencies of variables to 
determine the range and pattern of the wheelchair and medical factors recorded. 
T-tests were used with ratio and interval data to determine significant differences between 
sub-groups.  
This study was approved by the National Research Ethics Service. 
 
Results 
The sample consisted of 544 users mean age 44.6 (range 7-92, sd 20.4), 262 men mean age 
41.7 (range 8-82, sd 20.7) and 282 women mean age 47.2 (range 7-92, sd 19.7) years (Table 
1). One hundred and fifty seven were over 60. Ten users were aged 80+ and one was aged 92. 




All but 2 children were over 10 years old at assessment. There were more males in Groups 1 
and 2 and more females in Groups 3-5. Males were significantly younger than females (p < 
0.002 Two-tailed T-test).  
The largest diagnostic categories (Table 2) were CP (18.8%) and MS (16.5%). Males had 
conditions like MD and were younger whilst women had conditions such as MS and 
rheumatoid arthritis (RA) and were older. Three women were noted to have had a child whilst 
using an EPIOC. MS, CVD, RA, SCI, polio and amputation were not seen in Groups 1 and 2. 
Conversely, those with CP, MD, SB and amputation were not seen in Group 5. Of those users 
with known diagnoses (n=542), 438 (81%) had neurological or NNC and 155 (29%) had the 
progressive conditions of MS and MD. Diagnoses associated with childhood (CP, MD, SB 
and inherited/metabolic conditions) constituted 39% (n=212) of the cohort. 
Problematic pain was reported by 56 women and 43 men (18%) of the 544 users. There was 
no significant difference in age of those with or without problematic pain. Seventy six (77%) 
users reporting pain had NNC.  
Eighty three (15%) had scoliosis, kyphus or both. Of the 83 users with a (kypho)scoliosis, 53 
(64%) were provided with a TIS and 60 (72%) with SS. Forty one (49%) of those with 
scoliosis had CP or MD.  The majority were in Groups 2 and 3 (n=52; 63%). 
Equipment  
One hundred and sixty nine users (31%) were provided with SS (Table 3), with 99 (59%) 
provided to users with CP and MD. Despite the large number with MS, only 15 (9%) needed 
SS. Of 169 users with SS, 100 (59%) were in Groups 1 and 2. There were no statistically 
significant differences in the ages of those with or without SS. There were wide differences in 
diagnoses of users requiring SS. The majority of those with CP (n=64, 63%), and MD (n=35, 




54%) had SS whilst only one of 58 users with musculoskeletal conditions had SS (68 year old 
with obesity, severe cellulitis of legs and osteoarthritis of knees). 
Information on TIS was available from 489 (90%) of which 260 (53%) EPIOCs had this 
feature (Table 4). Users with TIS were significantly younger (mean 42.3, sd 21.1 years) than 
those without (mean 47.3, sd 19.3 years) (P<0.01). For those with MD, 65% were provided 
with TIS.    
Of those using TIS, only 92 had SS, mean age 29 (range 8-72, sd 17.8) years. They were not 
significantly different in age to those without SS (N=168) (mean 49.7, range 11-87, sd 19.2 
years). Eighty one (88%) users with both TIS and SS had NNC. Another notable group, 
although small, were those with inherited metabolic conditions where eight users had both 
TIS and SS.  
Complex control systems 
Fifty two (10%) users mean age 29 (range 10-69, sd 16 years) needed individualised 
adaptations to their control system. The commonest was tray-mounted controls provided to 
32(6%) users, predominately people with MD (n=14, mean age 20, range 11-33 years) and 
CP (n=11, mean age 27, range 16-48 years). Groups 1 and 2 accounted for 62% of users with 
complex controls.  Other approaches were light touch controls, head, chin and/or foot 
controls, non-standard switches, interfaces with other assistive technology and personal 
equipment (e.g. computers), different shaped control knobs and combinations of these 
features. 
Of the 52 provided with complex control systems, 35 (67%) had SS and 28(54%) had TIS. 
Nineteen (37%) had both SS and TIS and their diagnoses were CP (n=6), MD (n=9) and other 
(n=4).  Thirty two of the 35 users with complex controls systems and SS had NNC.  





Eleven (seven male) users (mean age 39.6 range 17-72, sd 21.8 years) required their 
wheelchair to accommodate their ventilation system including oxygen. Four had MD 
(including one man who worked part time), and others included motor neurone disease, 
Charcot-Marie-Tooth Disease, chronic obstructive airways disease, SCI, spinal muscular 
atrophy, severe spinal pain (following vertebral fractures due to osteoporosis secondary to 
Cushing’s syndrome) and Morquio’s Disease. Nine users with ventilation required TIS.  
These findings show that EPIOC users are a heterogeneous group in terms of diagnoses and 
the age at which a powered chair is provided. Younger groups require more complex 
equipment than older groups. The most complex cases had NNC.  
Discussion 
This is the first study, to our knowledge, describing a large cross-sectional cohort of users of 
a fleet of EPIOCs at a given time. Its uniqueness relates to consistent use of stringent 
eligibility criteria for EPIOC provision and users coming from a defined catchment area 
embracing inner city, suburban and country areas.  Our results demonstrate the diversity of 
EPIOC users across the age range and diagnoses. Noteworthy are the inclusion of individuals 
with rare diagnoses, mostly inherited metabolic conditions, not previously reported in cohorts 
of users studied over limited periods of time2;12;17;24.  
The findings bring together the objective data on the main technical considerations of EPIOC 
provision (SS, TIS and modified control systems) with the clinical information. This service 
was unusual as it had consultant physician support, as recommended16. This facilitated a 
more rigorous examination of medical issues and symptoms such as pain were identified and 
interventions initiated. This needs-led approach characterises the relationship between 




clinical features and EPIOC provision and may help to identify who would benefit from 
different features of PM irrespective of the nature of payers16. Our results contribute to 
current evidence by identifying the appropriate PM that is likely to meet the needs of this 
diverse group.   
There is no definitive or reliable data about the number of EPIOCS currently provided in the 
UK (Krys Jarvis, National Wheelchair Managers Forum - personal communication dated 12 
July 2012). Data from Tayside in Scotland indicates that Tayside had about twice the number 
of EPIOCs provided per population. It seems likely that the North West London region under 
provided EPIOCs as it provided 151 by December 1998 compared to 271 provided by the 
Northern Region of England during the same period for a roughly equivalent sized 
population.  
Group 1(0-15 years), 
In the UK, children under 11 years are more likely to be in one classroom for most of their 
lessons, whilst older children have an increased mobility requirement to move between 
teaching rooms and laboratories at secondary school. This probably explains the age range of 
this cohort. Whilst some children will have been provided with PM1 by charities e.g. Whizz-
Kidz , others may have had unmet needs. It is noteworthy that Whizz-Kidz changed their 
priorities for use of their funds after the provision of EPIOCs by the NHS. After EPIOC 
provision, Whizz-Kidz only funded PM for those who had not been provided with an EPIOC 
e.g. because of severe learning difficulties which precluded them from acquiring age-
appropriate independent use. Recently, the Wheelchair Service arranged with a children’s 
charity to meet the capital and maintenance costs of functions not provided by the NHS20.  
 




Recent recommendations emphasize the importance of motor and cognitive skills 
development and the ability to explore the environment as reasons for powered mobility 
being provided for very young children (aged 12-13 months onwards)25-27. In addition, early 
introduction of an EPIOC allows children and families to plan for future environmental 
adaptations and make proactive choices for housing and vehicles27. Consequently these issues 
need further publicity throughout the UK. 
This study shows that this group is dominated by those with CP and MD requiring SS 
reflecting the development of scoliosis (with/without kyphus) during teenage years21;28;29. Tilt 
and recline functions are also indicated in this Group who are susceptible to hip and other 
joint contractures30 and require pain and pressure relief13;29;30. EPIOCs provided for these 
children and those starting work are reported to facilitate greater functional mobility and to 
conserve energy for the physical demands of the workplace or college31. This has 
implications for payers or service commissioners as more chair functions will increase costs, 
in addition to the chair replacement costs consequent to user growth. 
Group 2 
EPIOC users in Group 2 (school leavers and young adults) may be seeking further education 
or their first employment. The majority of this group are users with CP and MD and our data 
indicate they are likely to need TIS and SS.  Groups 1 and 2 account for 61% of users 
needing complex control systems, significantly improving an individual's performance32. This 
has clear advantages for young adults entering further training or work5. 
Access to assisted mobility for young people aged 15-24 is crucial to successful transition 
from childhood to adulthood33. Research in young adults with SB has highlighted that under-
use of AT may delay successful transition to independent living and community 
participation34. Developing social and sexual relationships is a vital part of transition to 




adulthood. The independence provided by an EPIOC facilitates social activities leading to 
relationships1.  
Group 3 
Group 3 (those developing families, jobs and careers) had the largest number of EPIOC users 
(35%) reflecting conditions such as MS, CVD and RA. This group appears poorly 
represented in the literature and less is known about their needs when compared to young and 
old. Middle aged users are often grouped with older users in the literature35, despite having 
very different lifestyles and economic roles in society. Being neither children nor elderly, 
their specific needs are seldom addressed.  
Our findings demonstrate the provision of SS is low but with substantial numbers of users 
with MS and SCI, it is possible that they have residual motor functions sufficient to 
accommodate postural adjustments and movement in the chair and thus not need SS. 
Furthermore, acquired impairments in adult life are unlikely to give rise to a scoliosis. As TIS 
has become more available on EPIOCs (and less expensive), it may be prescribed more 
frequently, offering greater comfort13, improved pressure relief36 and relieving fatigue in 
conditions like MS.    
Individuals in this Group may be developing their families and EPIOC provision would need 
to accommodate demands of parenthood. Although the literature has begun to explore the 
issues of parenthood for some of the major diagnosis found in our data, e.g. MS37, SB38, and 
SCI39;40 we will also need more study of this issue for people with CP and MD as they live 
longer and may have expectations to become parents and to participate in child care these 
issues need addressing.  The three mothers reported in our group are likely to be an 
underestimate as our study did not explore social and family issues.  




As 10% of EPIOC users contribute to the working population5, difficulties travelling to work 
and appropriate job modifications require consideration during assessment41. 
Group 4 
This group (those reaching the end of employment and in active retirement) constitutes one 
third of this cohort and is dominated by those with MS and SCI. The small proportion with 
SS is consistent with the findings of Karmarkar et al7 who reported that older users were less 
likely to receive customised wheelchairs than their younger peers. This reflects the needs of 
users with predominantly acquired impairments with a reduced expectation of spinal 
deformity or limb contractures. Those ageing with probable comorbidities may need PM, 
particularly if their carer has age-related problems9.  
With 177 EPIOC users in Group 4 there will be a continuing demand for powered mobility 
with increasing age. In our experience, EPIOC withdrawal was unusual unless a user’s 
condition deteriorated, although this did occur episodically.     
Group 5 
This group (aged 75+) comprised the elderly with severely disabling condition(s). However, 
by meeting the assessment criteria2, they had potential for increased mobility and 
independence, suggesting those over 75 years (even up to age 92) should not be discounted 
from access to PM. Scandinavian data show important differences in use between older users 
aged between 65-76 and those aged between 77-92, indicating changing age-related needs 
(Brandt A. Paper read to the Canwheel conference, Toronto, 2011). Our results indicate no 
EPIOC users with CP, MD or inherited metabolic disorders in this age group in contrast to 
those in Groups 1-4. With improved life expectancy for those with illnesses presenting in 




childhood e.g. some muscular dystrophies42 there will be increases in the demand for PM as 
those in group 4 mature into group 5. 
Elderly people in the community do not commonly use high technology8. However, they are 
likely to demand wheelchair technologies43 to overcome social isolation, loneliness, 
decreased autonomy and loss of dignity . EPIOC provision contributes to active ageing, with 
increased activities, participation and community inclusion6;9;11.   
Study limitations  
This study excludes users who bought wheelchairs privately. Our data did not record those 
who did not meet the criteria for provision, nor those who may have been eligible but were 
not referred.  
As data were extracted from medical records that were designed for clinical use and not for 
research purposes, we experienced a small amount of missing information, an issue 
previously encountered by Karmarkar et al7. However, all data were extracted by the first 
author in a systematic manner.  
We did not gather data on participation, or on parenthood which would have provided a more 
complete picture of the 554 EPIOC users. However, this information has been published for 
subgroups drawn from this population1;9;11;12;29.  These studies demonstrated the limitations of 
NHS provision as well as considerable benefits to users and were most marked in the 
muscular dystrophy user group29. However, the data presented in this study represents the 
most appropriate EPIOC prescription that met the needs of each individual user according to 
the eligibility criteria – a limitation of the service. 




The data represents a cross-sectional survey at a particular time which may limit 
generalisability to other powered wheelchair populations. Service reorganisation prevented 
further follow up to evaluate benefits.   
Conclusions 
Those with congenital and inherited conditions account for almost 40% of the cohort. Due to 
the increased longevity of those with these conditions, our findings should inform future 
planning for payers of powered wheelchair services. These data confirm the increasing use of 
newer functions on powered wheelchairs (e.g. TIS). These features have associated additional 
costs and are provided predominantly to younger users, as is SS. This study provides 
outcomes of the EPIOC prescription for this heterogeneous group of very severely disabled 
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Table 1. Age and Sex of 544 EPIOC users 
 Age Group 1 (0-15y) Age Group 2 (16-24y) Age Group 3 (25-54y) Age Group 4 (55-74y) Age Group 5 (75+y) Total 
 N           mean (±sd) N           mean (±sd) N           mean (±sd) N           mean (±sd) N           mean (±sd) N           mean (±sd) 
Men  31          12.8(1.9) 54          20.3(2.4) 85           40.7(8.7) 79          62.7(5.2) 13          78.5(2.3) 262         41.7(20.7) 
Women 14          12.6(2.3) 45          20.2(2.4) 106         42.3(8.1) 98          63.6(5.7) 19          79.6(4.7) 282         47.2(19.7) 
Total 45          12.8(2.0) 99          20.3(2.4) 191         41.6(8.4) 177        63.2(5.5) 32          79.2(3.9) 544         44.6 (20.4) 
 


























Key: M = Male; N = Number; Age Group 1 = 0-15 years; Age Group 2 = 16-24 years; Age Group 3 =25-54 years; Age Group 4 = 55-74 years;  
Age Group 5 = over 75 years 
Diagnosis Age Group 1 Age Group 2 Age Group 3 Age Group 4 Age Group 5 Total 
 N %M N %M N %M N %M N %M %M N 
Multiple Sclerosis 0  0  30 37 52 27 8 38 31 90 
Cerebral Palsy 11 73 46 41 38 47 7 43 0  47 102 
Muscular Dystrophy 21 86 25 88 16 50 3 100 0  78 65 
Cerebrovascular Disease 0  0  9 33 18 61 5 60 53 32 
Rheumatoid Arthritis 0  0  5 40 12 33 2 50 37 19 
Other Musculo-skeletal 0  1 0 10 10 19 58 9 22 36 39 
Other Neurological 6 50 9 44 23 57 19 42 3 33 48 60 
Spina Bifida 1 0 3 33 10 20 3 33 0  24 17 
Spinal Cord Injury 0  0  30 63 25 60 2 50 61 57 
Polio 0  0  5 40 9 33 1 100 40 15 
Amputation 0  0  0  6 67 0  67 6 
Mixed impairments 0  2 50 4 25 1 100 1 0 38 8 
Other 0  0  1 0 1 100 1 100 66 3 
Not known 0  1 0 1 0 0  0  0 2 
Inherited/metabolic 6 33 12 58 9 56 2 0 0  48 29 
Total 45 69 99 54 191 45 177 79 32 41 48 544 








Key: N=number; For Age Groups 1-5, see Table 2 key 
Diagnosis Age Group 1 Age Group 2 Age Group 3 Age Group 4 Age Group 5 Total 
 N % SS N %SS  N % SS N %SS  N  %SS N  %SS 
Multiple Sclerosis 0   0   30 13 52 19 8 
13 90 17 
Cerebral Palsy 11 100 46 78 38 40 7 27 0 
  102 63 
Muscular Dystrophy 21 71 25 64 16 25 3   0 
  65 54 
Cerebrovascular Disease 0   0   9 11 18 6 5   32 6 
Rheumatoid Arthritis 0   0   5   12   2   19   
Other Musculo-skeletal 0   1   10   19 5 9 
  39 3 
Other Neurological 6 67 9 44 23 35 19 5 3   60 28 
Spina Bifida 1 100 3 67 10 30 3 67 0   17 47 
Spinal Cord Injury 0   0   30 23 25 12 2   57 18 
Polio 0   0   5   9 33 1   15 20 
Amputation 0   0   0   6   0   6   
Mixed impairments 0   2 100 4   1   1   8 75 
Other 0  0   1   1   1   3   
Not known 0   1   1   0   0   2   
Inherited/metabolic 6 50 12 50 9 33 2   0   29 41 
Total 
45 76 99 67 191 24 177 13 32 3 544 31 




Table 4. Provision of Tilt-in-Space feature (%TIS) for 489 EPIOC users according to their age group 
and diagnosis. 
 
Key: N= number;  For Age Groups 1-5, see table 2 key. 




Age Group 3 Age Group 4 Age Group 5 Total 
 N  %TIS N %TIS N %TIS N %TIS N %TIS N %TIS 
Multiple Sclerosis 0  0  27 41 47 53 7 43 81 49 
Cerebral Palsy 11 73 36 50 36 56 7 71 0   90 57 
Muscular 
Dystrophy 
21 67 20 75 16 56 3 33 0   60 65 
Cerebrovascular 
Disease 
0   0   8 38 14 50 5 60 27 48 
Rheumatoid 
Arthritis 
0   0   5 20 11 46 2 0 18 33 
Other Musculo-
skeletal 
0   1 100 7 86 18 33 7 27 33 46 
Other Neurological 5 60 9 44 20 65 17 59 2 50 53 58 
Spina Bifida 1 100 3 33 10 40 3 33 0   17 41 
Spinal Cord Injury 0   0   27 41 21 48 2 50 50 44 
Polio 0   0   4 75 9 44 1 100 14 57 
Amputation 0   0   0   6 50 0  6 50 
Mixed impairments 0   2 100 4 50 1 0 1 100 8 63 
Other 0  0   1 0 1 0 1 100 3 33 
Not known 0   0  1 0 0   0   1 0 
Inherited/metabolic 5 60 12 83 9 67 2 50 0   28 71 
Total 43 67 82 61 175 60 160 49 28 46 489 53 
